<DOC>
	<DOCNO>NCT00022217</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving one drug give drug different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness cisplatin-epinephrine injectable gel plus paclitaxel carboplatin treat patient recurrent head neck cancer .</brief_summary>
	<brief_title>Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel Carboplatin Treating Patients With Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity intratumoral cisplatin-epinephrine injectable gel systemic paclitaxel carboplatin patient recurrent squamous cell carcinoma head neck . II . Determine safety regimen patient population . III . Determine time progression , pattern progression , rate relapse patient treat regimen . VI . Determine time response duration response patient treat regimen . V. Determine overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive cisplatin-epinephrine gel intratumorally day -15 , -8 , 1 , 8 , 15 , 22 course 1 day 1 , 8 , 15 , 22 subsequent course . Patients also receive paclitaxel IV least 3 hour follow carboplatin IV least 30 minute day 1 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients achieve local complete response ( CR ) metastatic disease progression continue treatment carboplatin paclitaxel . Patients achieve total CR may receive 2 additional course carboplatin paclitaxel . Patients follow 1-4 week every 3 month thereafter . PROJECTED ACCRUAL : Approximately 40 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent primary squamous cell carcinoma head neck The following histological type also eligible : Epithelial carcinoma Verrucous carcinoma Sarcomatoid squamous cell carcinoma Lymphoepithelioma Pseudosarcoma Anaplastic carcinoma Transitional cell carcinoma At first relapse prior definitive surgery , radiotherapy , and/or chemotherapy candidate potentially curative salvage surgery salvage radiotherapy Relapsed metastatic disease one follow primary head neck area metastatic site skin soft tissue accessible local injection : Oral cavity ( include tongue , floor mouth , uvula , tonsil ) Hypopharynx Larynx Nasopharynx Paranasal sinus Salivary gland Tridimensionally measurable disease Tumor great 20 cm3 At immediate risk invasion major vessel extracranial vascular system ( e.g. , common , internal , external carotid artery vertebral artery ) Amenable direct injection physical exam , ultrasound , CT guidance Visceral metastasis ( e.g. , lung ) allow eligible injection cisplatinepinephrine gel PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Platelet count least 100,000/mm3 Neutrophil count least 1,500/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 3 mg/dL AST great 3 time upper limit normal ( ULN ) Alkaline phosphatase great 3 time ULN Albumin great 2.5 g/dL PT within 3 second normal Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 50 mL/min Cardiovascular : See Disease Characteristics No New York Heart Association class III IV heart disease Other : No malignancy within past 5 year except nonmelanoma skin cancer outside area plan cisplatinepinephrine gel treatment No known hypersensitivity cisplatin , carboplatin , paclitaxel , bovine collagen , epinephrine , sulfites No infection require parenteral antibiotic No medical psychiatric condition would preclude informed consent Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 28 day since prior chemotherapy recover Prior carboplatin taxanes allow , combination Endocrine therapy : Concurrent stabledose prednisone/prednisolone chronic disease allow Concurrent stabledose corticosteroid inhalant asthma prophylaxis allow Concurrent dexamethasone antiemetic allow Radiotherapy : See Disease Characteristics At least 28 day since prior radiotherapy recover Concurrent limitedfield radiotherapy symptomatic metastatic disease amenable cisplatinepinephrine gel allow Surgery : See Disease Characteristics At least 28 day since prior surgery recover Other : No concurrent anesthetics topical preparation contain epinephrine No concurrent cancer therapy No drug interact cisplatin ( e.g. , probenecid thiazide ) 28 day study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2002</verification_date>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>salivary gland anaplastic carcinoma</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>